EIT Health: AI and Ethics in the Health Innovation Community

An extensive survey was run by the EIT Health amongst startups and innovators. The survey is one-to-one with the AI & Ethics guidelines. In addition a set of case studies has been collected. All was presented and discussed at the World Health Summit in Berlin, 27 October 2019. An extensive report about the survey and cases and with recommendations is available. An op-ed was published in Science|Business.

1129803_eit_health_whs_report_final.pdf
(10.09 MB - PDF)
Downloaden
Tags
survey health ageing recommendations EIT health cases

Comments

Profile picture for user ntimmpul
Geplaatst door Paul TIMMERS op za, 11/23/2019 - 09:51

You can also find information about the World Health Summit debate on AI & ethics.

Profile picture for user njastrno
Geplaatst door Norbert JASTROCH op za, 11/23/2019 - 19:46

 Dear Paul Timmers,

The central problem, that of the balance between regulation and innovation, seems to be somehow similar to a problem discussed in A. Nassehi et al, The Strength of Weak Procedures, Zeitschrift fuer Soziologie 48(3), de Gruyter Oldenbourg 2019, https://doi.org/10.1515/zfsoz-2019-0015on the subject of organ donation. The problem they discuss in the context of organ allocation for transplantation is that of fundamentally diverging perspectives which make a specific question unresolvable in a general sense.

They argue that instead of trying to force obligatory political decision, it is more promising to organize an institutionalized permanent ethical reflection on the subject under consideration. 

Taking such an approach and transferring it to the issue of balancing regulation and innovation in the field of AI may offer a way how to deal with the fundamental perspective differences you address.

Regards, Norbert Jastroch

 

 

Als antwoord op door Norbert JASTROCH

Profile picture for user ntimmpul
Geplaatst door Paul TIMMERS op zo, 11/24/2019 - 09:24

Dear Norbert, very valuable comment, thanks! As regards the governance perspective and coming out of our survey and case studies is the practice of post-market surveillance in the medical devices and pharma field. Combined with pre-market impact assessment this suggests at least two governance mechanisms that can be institutionalized, i.e. mandated by law. These would well go together with the institutionalized ethical reflection that you refer to (checks & balances) in order to create more space for responsible and fast innovation.

Best regards, Paul

Als antwoord op door Paul TIMMERS

Profile picture for user njastrno
Geplaatst door Norbert JASTROCH op di, 11/26/2019 - 18:32

Dear Paul,

one could expect these three elements - proactive regulation, reactive evaluation, and steady ethical reflection exercise - to build a promising innovation pathway. It's all about combining them economically reasonable, and institutionalize them in a prudent way. 

Kindly, Norbert 

 

Profile picture for user ngaursac
Geplaatst door Sachin GAUR op ma, 11/25/2019 - 02:42

Dear Paul, 

Thanks for sharing. I believe for healthcare especially regulation is needed to bring confidence among clinicians for uptake of AI. We have seen some very interesting examples of AI systems being used in parallel with the human experts. It is interesting to see the false positives and negatives in a clinical setting and the possible implication of the same on the patient's life if the human expertise was not available and vice versa. (so both approaches have their shortcomings and together they seem to be an improved system). 

I can share more with you offline exact examples on these AI vis-a-vis Human expert in clinical setting. 

 Thanks 

-Sachin